Pulmonary function at school-age in surfactant-treated preterm infants

Pediatric Pulmonology

Volumn 27, Issue 3, 1999, Pages 191-198

  Gappa, Monika ^a,e   Berner, Michael M ^b   Hohenschild, Stephan ^b   Dammann, Christiane E L ^c   Bartmann, Peter ^d  

^a Children's Hospital Hannover   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Airway resistance; Bronchopulmonary dysplasia; Long term outcome; Lung volume; Prematurity; Randomized controlled clinical trial; Respiratory function; Spirometry; Surfactant

Indexed keywords

LUNG SURFACTANT; PLACEBO;

AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ARTICLE; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPIRATORY FLOW; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; INFANT; LUNG FUNCTION; MULTICENTER STUDY; NEWBORN MORBIDITY; PEAK EXPIRATORY FLOW; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME; VITAL CAPACITY;

ADOLESCENT; AGE FACTORS; BODY HEIGHT; CHI-SQUARE DISTRIBUTION; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LIPIDS; MALE; PATIENT COMPLIANCE; PHOSPHOLIPIDS; PROGNOSIS; PULMONARY SURFACTANTS; REFERENCE VALUES; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY FUNCTION TESTS;

EID: 0032949425     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199903)27:3<191::AID-PPUL7>3.0.CO;2-Z     Document Type: Article

References (31)

1. Fujiwara T, Maeta H, Chida S, Morita H, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980;1(8159):55-59.
2. Avery M, Merritt T. Surfactant-replacement therapy. N Engl J Med 1991;324:910-912.
3. Goldsmith L, Greenspan J, Rubenstein S, Wolfson M, Shaffer T. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distension. J Pediatr 1991;119:424-428.
4. Gortner L, Bartmann P, Pohlandt F, Bernsau U, Porz F, Hellwege H, Seitz R, Hieronimi G, Bremer C, Jorch G, Hentschel R, Reiter H, Wolf H, Ball F. Early treatment of respiratory distress syndrome with bovine surfactant in very preterm infants: a multicenter controlled clinical trial. Pediatr Pulmonol 1992; 14:4-9.
5. Long W, Thompson T, Sundell H, Schumacher R, Volberg F, Guthrie R, American Exosurf Neonatal Study Group I. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700-to 1350-gram infants with respiratory distress syndrome. J Pediatr 1991;118:595-605.
6. Merritt T, Hallman M, Berry C, Pohjavuori M, Edwards D III, Jaaskelainen J, Grafe M, Vaucher Y, Wozniak P, Heldt G, Rapola J. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991;118:581-594.
7. Morley C. Surfactant treatment for premature babies - a review of clinical trials. Arch Dis Child 1991;66:445-450.
8. OSIRIS. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. Lancet 1992;340: 1363-1369.
9. Abbasi S, Bhutani V, Gerdes J. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants treated with exogenous surfactant. J Pediatr 1993;122:446-452.
10. Couser RJ, Ferrara TB, Wheeler W, McNamara J, Falde B, Johnson K, Hoekstra RE. Pulmonary follow-up 2.5 years after a randomized, controlled, multiple dose bovine surfactant study of preterm newborn infants. Pediatr Pulmonol 1993;15:163-167.
11. Walti H, Boule M, Moriette G, Relier J. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant. Biol Neonate 1992;61:48-53.
12. Yuksel B, Greenough A, Gamsu H. Respiratory function at follow-up after neonatal surfactant replacement therapy. Respir Med 1993;87:217-221.
13. Kramer B, Sinkin R, Merzbach J, Myers G, Brooks J, Palumbo D, Cox C, Kendig J, Phelps D. Improved pulmonary outcome at school age with prophylactic surfactant administration. Pediatr Res 1995;37:263.
14. Wagner C, Kramer B, Kendig J, Brooks J, Cox C, Phelps D. Neurodevelopmental and pulmonary outcome of 40 premature infants at 5-7 years: surfactant vs. saline at birth. Pediatr Res 1992;31:263.
15. American Thoracic Society. Standardization of spirometry - 1987 update. Am Rev Respir Dis 1987;136:1285-1298.
16. Taussig L, Chernick V, Wood R. Standardization of lung function testing in children. J Pediatr 1980;97:668-676.
17. Pfaff J, Morgan W. Pulmonary function in infants and children. Pediatr Clin North Am 1994;41:401-423.
18. Quanjer P, Stocks J, Polgar G, Wise M, Karlberg J, Borsboom G. Compilation of reference values for lung function measurements in children. Eur Respir J 1989;2:184-261.
19. Toce S, Farrell P, Leavitt L, Samuels D, Edwards D. Clinical and roentgenographic scoring systems for assessing bronchopulmonary dysplasia. Am J Dis Child 1984;138:581-585.
20. Hakulinen A, Heinonen K, Länsimies E, Kiekara O. Pulmonary function and respiratory morbidity in school-age children born prematurely and ventilated for neonatal respiratory insufficiency. Pediatr Pulmonol 1990;8:226-232.
21. Farstad T, Brockmeier F, Bratlind D. Cardiopulmonary function in premature infants with bronchopulmonary dysplasia - a 2-year follow up. Eur J Pediatr 1995;154:853-858.
22. MacLusky I, Stringer D, Zarfen J, Smallhorn J, Levison H. Cardiorespiratory status in long-term survivors of prematurity, with and without hyaline membrane disease. Pediatr Pulmonol 1986;2:94-102
23. Phibbs R, Ballard R, Clements J, Heilbron D, Phibbs C, Schlueter M, Sniderman S, Tooley WH, Wakeley A. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics 1991;88:1-9.
24. Smyth J, Tabachnik E, Duncan W, Reilly B, Levison H. Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia. Pediatrics 1981;68:336-340.
25. Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein specific antibodies in sera of premature infants treated with survanta, a modified bovine surfactant. Pediatrics 1991;87:505-510.
26. Bartmann P, Bamberger U, Pohlandt F. Gortner L. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1). Acta Paediatr Scand 1992;81:383-388.
27. Morgan W, Martinez F. Risk factors for developing wheezing and asthma in childhood. Pediatr Clin North Am 1992;39:1185-1203.
28. McCormick M. Has the prevalence of handicapped infants increased with improved survival of the very low birthweight infant? Clin Perinatal 1993;20:263-277.
29. Northway W, Moss RB, Carlisle KB, Parker BR, Popp RL, Pitlick PT, Eichler I, Lamm RL, Brown BW. Late pulmonary sequlae of bronchopulmonary dysplasia. N Engl J Med 1990;323:1793-1799.
30. Blayney M, Kerem E, Whyte H, O'Brodovich H. Bronchopulmonary dysplasia: improvement of lung function between 7 to 10 years of age. J Pediatr 1991;118:201-206.
31. Doyle L, Kitchen W, Ford G, Rickards A, Kelly E, Callanan C, Raven J, Olinsky A. Outcome to 8 years of infants <1000g birth-weight: relationship with neonatal ventilator and oxygen therapy. J Paediatr Child Health 1991;27:184-188.